Pfizer (PFE)
(Delayed Data from NYSE)
$28.09 USD
-0.21 (-0.74%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $28.11 +0.02 (0.07%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.09 USD
-0.21 (-0.74%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $28.11 +0.02 (0.07%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Johnson & Johnson (JNJ) Q4 Earnings Top Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 5.86% and 0.22%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Concert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout Offer
by Zacks Equity Research
Concert Pharmaceuticals (CNCE) enters into a definitive agreement to be acquired by India-based Sun Pharmaceutical for $576 million. Stock up 17% in the previous week.
Pfizer (PFE) Stock Moves -0.09%: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $44.96, marking a -0.09% move from the previous day.
Novavax (NVAX) Gets Nod for COVID-19 Booster Jab in South Korea
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine gets approval in South Korea as a booster dose in adults 18 years and older.
The Zacks Analyst Blog Highlights Pfizer, Abbott Laboratories, Union Pacific Corporation, Citigroup and Intuitive Surgical.
by Zacks Equity Research
Pfizer, Abbott Laboratories, Union Pacific Corporation, Citigroup and Intuitive Surgical are part of the Zacks top Analyst Blog.
J&J (JNJ) Discontinues HIV Vaccine Phase III Mosaico Study
by Zacks Equity Research
J&J (JNJ) discontinues phase III study on its investigational HIV vaccine regimen, which shows that the candidate lacks efficacy in preventing HIV.
Top Analyst Reports for Pfizer, Abbott Laboratories & Union Pacific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Abbott Laboratories (ABT) and Union Pacific Corporation (UNP).
Moderna (MRNA) Up on Upbeat Data From Phase III Study on RSV Jab
by Zacks Equity Research
Data from a late-stage study showed that Moderna's (MRNA) RSV vaccine was 83.7% effective at preventing at least two symptoms in adults aged 60 and older.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Is Invesco Dynamic Large Cap Value ETF (PWV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWV
Valneva (VALN) Stock Down 61.5% in the Past Year: Here's Why
by Zacks Equity Research
Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.
Deciphera (DCPH) Rises 70% in the Past 6 Months: Here's Why
by Zacks Equity Research
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $47.62 in the latest trading session, marking a -1.59% move from the prior day.
Novavax (NVAX) Names John Jacobs as New CEO, Shares Rise
by Zacks Equity Research
Novavax (NVAX) appoints John C. Jacobs as its new president and chief executive officer, effective Jan 23, 2023.
FDA Accepts Pfizer's (PFE) sBLA Filing for Pneumococcal Jab
by Zacks Equity Research
The FDA grants priority review to Pfizer's (PFE) filing seeking label expansion of its pneumococcal 20-valent conjugate vaccine in infants and children. A decision is expected by this April.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Deciphera (DCPH) Issues Strategic & Corporate Outlook for 2023
by Zacks Equity Research
Deciphera (DCPH) provides a strategic outlook and planned corporate milestones for 2023. The company also posts preliminary fourth-quarter and 2022 revenues.
Why Pfizer (PFE) Could Beat Earnings Estimates Again
by Zacks Equity Research
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $51.26, marking a +0.04% move from the previous day.